Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920380 | 0.83 | LTA4H (0.35) | SLC22A6LTA4H | |
| SCHEMBL28914089 | 0.76 | SLC22A6 (0.36) | SLC22A6 | |
| SCHEMBL2968549 | 0.74 | USP2 (0.35) | SLC22A6 | |
| SCHEMBL17583759 | 0.74 | CA1 (0.34) | SLC22A6 | |
| SCHEMBL31147863 | 0.74 | CA1 (0.34) | SLC22A6 | |
| SCHEMBL475683 | 0.73 | — | — | |
| SCHEMBL14395757 | 0.73 | SLC22A6 (0.33) | SLC22A6 | |
| SCHEMBL1920397 | 0.71 | — | — | |
| SCHEMBL1920398 | 0.71 | — | — | |
| SCHEMBL509933 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695119-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8580859-B2 | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-102171185-A | Methionine analogs and methods of using same | BIOXINESS PHARMACEUTICS INC | 2011-08-31 | — | — | CN | disclosed |
| EP-2326619-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | Bioxiness Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014943-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267632-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | SLC22A6 4665/4885LTA4H 2320/4885 |
| US-20150329481-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | SLC22A6 4665/4885LTA4H 2320/4885 |
| US-20170029369-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | SLC22A6 4665/4885LTA4H 2320/4885 |
| US-20140142189-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | SLC22A6 4665/4885LTA4H 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.